BeiGene's TEVIMBRA Gains FDA Panel Support for PD-1 Inhibitors in Advanced Esophageal and Gastric Cancers
Portfolio Pulse from Benzinga Newsdesk
BeiGene's TEVIMBRA receives FDA panel support for use in advanced esophageal and gastric cancers with PD-L1 expression >1%. The FDA's Oncologic Drugs Advisory Committee voted in favor of a class-wide PD-L1 expression level cut-off for PD-1 inhibitors in these cancers.
September 27, 2024 | 7:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BeiGene's TEVIMBRA has received support from the FDA's Oncologic Drugs Advisory Committee for its use in treating advanced esophageal and gastric cancers with PD-L1 expression >1%. This support could lead to increased adoption and sales if FDA approval follows.
The FDA panel's support is a significant step towards full approval, which could enhance TEVIMBRA's marketability and sales. The positive vote for PD-L1 >1% expression aligns with the drug's target patient group, potentially increasing its use.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100